ST. PAUL, MN, Sep 24, 2013 (Marketwired via COMTEX) -- EnteroMedics Inc.
(NASDAQ: ETRM), "We are very encouraged by the responsiveness of the FDA and are confident in
our ability to address their questions in a timely manner," said Mark B.
Knudson, Ph.D., EnteroMedics' President and Chief Executive Officer. "We will
continue to work closely with the FDA throughout this process. We believe that
the Company continues on track for a panel in late Q4 2013/Q1 2014 with approval
decision in the first half of 2014."